Table 1.
MEP amplitude and stimulation intensity before and after reboxetine (RBX) administration
| Stimulation | TMS parameter | Drug Condition | Baseline 1 | Baseline 2 | Baseline 3 | P |
|---|---|---|---|---|---|---|
| Anodal | MEP (mV) | PLC | 1.04 ± 0.12 | 0.98 ± 0.09 | 0.99 ± 0.06 | 0.396 |
| Acute RBX | 1.01 ± 0.03 | 0.95 ± 0.18 | 1.03 ± 0.16 | 0.153 | ||
| Chronic RBX | 1.04 ± 0.11 | 1.07 ± 0.08 | 1 ± 0.07 | 0.357 | ||
| % MSO | PLC | 52 ± 8.07 | 52 ± 8.07 | 50.3 ± 6.74 | 0.178 | |
| Acute RBX | 52.9 ± 7.11 | 52.9 ± 7.11 | 53.1 ± 7.56 | 0.445 | ||
| Chronic RBX | 52.1 ± 7.18 | 52.1 ± 7.18 | 51.4 ± 8.5 | 0.325 | ||
| Cathodal | MEP (mV) | PLC | 1.03 ± 0.14 | 0.99 ± 0.12 | 1.01 ± 0.09 | 0.517 |
| Acute RBX | 1.01 ± 0.13 | 0.97 ± 0.09 | 0.99 ± 0.08 | 0.946 | ||
| Chronic RBX | 0.94 ± 0.06 | 1.03 ± 0.12 | 1 ± 0.09 | 0.063 | ||
| % MSO | PLC | 52.9 ± 7.54 | 52.9 ± 7.54 | 53.3 ± 8.09 | 0.801 | |
| Acute RBX | 51.6 ± 6.19 | 51.6 ± 6.19 | 51.3 ± 7.43 | 0.163 | ||
| Chronic RBX | 51.9 ± 7.62 | 51.9 ± 7.62 | 51.3 ± 7.6 | 0.096 |
Shown are the mean MEP amplitudes ± SD and stimulation intensity (percentage of maximum stimulator output, %MSO) mean ± SD of baseline 1, 2 and 3. The intensity of TMS was determined to elicit MEPs with a peak to peak amplitude of ∼1 mV (baseline 1). A second baseline (baseline 2) was recorded 2 h after medication intake to determine the effect of the drug on cortical excitability and adjusted if necessary (baseline 3). Student's t tests revealed no significant differences between conditions (P > 0.05).